REBECCA MAXWELL: Open Payments
NPI 1235757238 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,920 in 91 payments from 25 companies in 2025. Trend: 2023 $1,204 · 2024 $1,124 · 2025 $2,920
Food & beverage: $2,020Consulting: $900
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $1,120 |
| GENZYME CORPORATION | 20 | $343 |
| AstraZeneca Pharmaceuticals LP | 14 | $308 |
| Regeneron Healthcare Solutions, Inc. | 11 | $177 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $123 |
| Inspire Medical Systems, Inc. | 1 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Philips North America LLC | 3 | $76 |
| Merck Sharp & Dohme LLC | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $67 |
Products named: NUCALA, DUPIXENT, INSPIRE, FASENRA, BREZTRI, Vest Therapy Und, WINREVAIR, Adempas.
Industry payments across CO — which companies pay providers there.
